Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/94329
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKhanna, D.en
dc.contributor.authorMittoo, S.en
dc.contributor.authorAggarwal, R.en
dc.contributor.authorProudman, S.en
dc.contributor.authorDalbeth, N.en
dc.contributor.authorMatteson, E.en
dc.contributor.authorBrown, K.en
dc.contributor.authorFlaherty, K.en
dc.contributor.authorWells, A.en
dc.contributor.authorSeibold, J.en
dc.contributor.authorStrand, V.en
dc.date.issued2015en
dc.identifier.citationThe Journal of rheumatology, 2015; 42(11):2168-2171en
dc.identifier.issn0315-162Xen
dc.identifier.issn1499-2752en
dc.identifier.urihttp://hdl.handle.net/2440/94329-
dc.description.abstractOBJECTIVE: Interstitial lung disease (ILD) is common in connective tissue disease (CTD) and is the leading cause of mortality. Investigators have used certain outcome measures in randomized controlled trials (RCT) in CTD-ILD, but the lack of a systematically developed, CTD-specific index that captures all measures relevant and meaningful to patients with CTD-ILD has left a large and conspicuous gap in CTD-ILD research. METHODS: The CTD-ILD working group, under the aegis of the Outcome Measures in Rheumatology (OMERACT) initiative, has completed a consensus group exercise to reach harmony on core domains and items for inclusion in RCT in CTD-ILD. During the OMERACT 12 meeting, consensus was sought on domains and core items for inclusion in RCT. In addition, consensus was pursued on a definition of response in RCT. Consensus was defined as ≥ 75% agreement among the participants. RESULTS: OMERACT 12 participants endorsed the domains with minimal modifications. Clinically meaningful progression for CTD-ILD was proposed as ≥ 10% relative decline in forced vital capacity (FVC) or ≥ 5% to < 10% relative decline in FVC and ≥ 15% relative decline in DLCO. CONCLUSION: There is consensus on domains for inclusion in RCT in CTD-ILD and on a definition of clinically meaningful progression. Data-driven approaches to validate these results in different cohorts and RCT are needed.en
dc.description.statementofresponsibilityDinesh Khanna, Shikha Mittoo, Rohit Aggarwal, Susanna M. Proudman, Nicola Dalbeth, Eric L. Matteson, Kevin Brown, Kevin Flaherty, Athol U. Wells, James R. Seibold, and Vibeke Stranden
dc.language.isoenen
dc.publisherJournal of Rheumatology Publishingen
dc.rightsCopyright © 2015. All rights reserved.en
dc.subjectHumans; Lung Diseases, Interstitial; Connective Tissue Diseases; Severity of Illness Index; Incidence; Survival Analysis; Follow-Up Studies; Comorbidity; Adult; Aged; Middle Aged; Societies, Medical; Disease Management; Female; Male; Consensus Development Conferences as Topic; Randomized Controlled Trials as Topic; Outcome Assessment, Health Careen
dc.titleConnective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) - report from OMERACT CTD-ILD Working Groupen
dc.typeJournal articleen
dc.identifier.rmid0030024398en
dc.identifier.doi10.3899/jrheum.141182en
dc.identifier.pubid176366-
pubs.library.collectionMedicine publicationsen
pubs.library.teamDS01en
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
dc.identifier.orcidProudman, S. [0000-0002-3046-9884]en
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.